Translating discoveries from bench to bedside is a challenging process and allows us do advance scientific discoveries and ensures that government-funded research translates into improved health for our society. The SPARK training program helps to understand clinical needs, develops a target product profile and strengthens project management abilities. These essential tools not only increase the likelihood of success, but also help decrease both the cost and time required to accomplish this goal (“de-risking”).
The Transfer Unit supports research labs to develop small molecules or biologicals or treatments of unmet clinical needs, respectively, with the aim to advance projects for any indication with high potential impact. To achieve this goal we utilize a variety of molecular and cell based techniques as well as different animal models.
The facility offers advisory, financial and personnel support, including:
- Funds to asses and to de-risk your project
- Funds to actually run a project
- Implementation and execution of assays, e.g. toxicity assay, dose-response assay
- Advice from SPARK advisory board, consisting of experts with translational experience
- Mentored project management support
- Help to establish defensible Intellectual Property
- Training on what translation is all about
- Education on drug and diagnostic development
- Introduction to of the SPARK international network
We are currently using and offering support for the following assays and techniques:
- Cell culture (primary and tumor cell lines, mouse and human)
- Toxicity tests
- Viability tests
- Protein purification - see also Core Service Protein Production
- Western Blot analysis, RNA purification
- qPCR analysis
- siRNA & shRNA - see also Core Facility Functional Genomics
- Virus production
GO BIO Initial - call open. Deadline: February 15th 2024. Through its "GO-Bio initial funding programmthe German Ministray ofEducation and Research (BMBF) aims to identify and develop early research ideas in life science that hav a clear potentioal fo innovation. The Core Facility Technology Transfer will help you with grant application. More information
For further questions, please contact the CF manager Sonja Schätzlein.
BioVaria 2024. BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe. This event brings together Europe‘s leading tech transfer professionals, innovators from academia and startups with investors and representatives of the global biotech and pharma industry. Selected startups from all life-science areas will be offered the chance to pith their venture live in front of the BioVaria Startup Jury members - Call open - Deadline February 15th 2024. From 29-30 April 2024 in Munich. More information
Leibniz Conference on Bioactive Compounds 2024. Deadline: March 25th 2024
We cordially invite you to the upcoming Leibniz Conference on Bioactive Compounds 2024, which will be hosted by the Leibniz Institute on Aging – Fritz Lipmann Institute. This year, the best poster will be awarded a prize of €500.
Registration and further information can be found here. Please send abstracts by email to: wirkstoffe@~@ipb-halle.de.
SPARK Europe Webinar Series - Programm 2024
- Wednesday, February 7 , 2024 / SPARK Tel Aviv / Intro to Market Research / Nadav Ofir
- Wednesday, March 6 , 2024 / SPARK BIH / Drug Repurposing / Hans Platteeuw
A free sample of the published book, “SPARK: A Practical Guide to Drug Development in Academia”, by Daria Mochly-Rosen and Kevin Grimes will be given to our SPARKees.
External guests are welcome to join our educational forum series (Wednesday 5-7PM in Golgi). Project presentations are only accessible with signed CDA.